<bill session="117" type="s" number="2837" updated="2023-03-08T20:12:35Z">
  <state datetime="2021-09-23">REFERRED</state>
  <status>
    <introduced datetime="2021-09-23"/>
  </status>
  <introduced datetime="2021-09-23"/>
  <titles>
    <title type="display">340B Accountability Act of 2021</title>
    <title type="official" as="introduced">A bill to amend the Public Health Service Act to clarify rules relating to drug discounts for covered entities.</title>
    <title type="short" as="introduced">340B Accountability Act of 2021</title>
  </titles>
  <sponsor bioguide_id="B001310"/>
  <cosponsors/>
  <actions>
    <action datetime="2021-09-23">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-09-23" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-06-30T22:22:05Z" status="Introduced in Senate">340B Accountability Act of 2021

This bill requires participants in the 340B drug pricing program to allow the Health Resources &amp; Services Administration (HRSA) to audit their records to determine how they use the net income from the discounted drug prices under the program. Participants also must retain records and reports as necessary for HRSA to perform the audits.</summary>
</bill>
